BriaCell Therapeutics shares are trading lower by 40% Thursday afternoon. The company announced the pricing of a $5.5 million ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety Monitoring Board ...

Briacell Therapeutics Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.03%. The profit margin, also known as the revenue ratio or gross profit ...

BriaCell Therapeutics (BCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily ...

BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company, Thursday announced the pricing of an underwritten public ...

The notes will be senior, unsecured obligations of Nutanix. The notes will bear interest at a rate of 0.50% per year. Interest will be payable semi-annually in arrears on June 15 and December 15 of ...

PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months ...

Equities researchers at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for BriaCell Therapeutics in a ...

Stock analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for BriaCell Therapeutics in a report ...